Biogen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biogen sits in the top decile of US sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count).
Biogen: 334 sponsored US clinical trials, 21 recruiting.
Biogen sponsors 334 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 237 completed. 84 of these trials are in Phase 3-4 (later-stage) and 198 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 13 trials.
Top-decile sponsor footprint
Biogen ranks in the top decile of sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
237 of 302 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
334 total, page 4 of 7
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
NCT02462759
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
NCT02477800
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
NCT02525874
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
NCT02459886
Tecfidera Lymphocyte Chart Review
NCT02519413
Single-Dose Study of a New Formulation of BIIB061
NCT02521545
Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)
NCT02443740
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
NCT02386553
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
NCT02255422
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
NCT02430532
Tecfidera Slow-Titration Study
NCT02428231
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
NCT02422407
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
NCT02410278
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
NCT02097849
Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
NCT02343159
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects
NCT02341482
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
NCT02255435
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
NCT02332798
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
NCT02294851
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
NCT02342704
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
NCT02292537
Plegridy Observational Program
NCT02230969
Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery
NCT02283918
RTA 408 Capsules in Patients With Melanoma - REVEAL
NCT02259231
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
NCT02269930
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
NCT02241785
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
NCT02228395
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
NCT02219932
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02283853
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
NCT02193074
Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers
NCT02228707
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
NCT02201849
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
NCT02159573
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
NCT02142959
A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
NCT02171208
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
NCT02128113
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
NCT02036970
Pilot Tape Harvesting Study
NCT02125695
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
NCT02106897
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
NCT02065375
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)
NCT02052791
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
NCT01955707
RTA 408 Lotion in Healthy Volunteers
NCT02029716
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
NCT02029729
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
NCT02071121
Dimethyl Fumarate (DMF) Observational Study
NCT02047097
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
NCT01939002
BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis
NCT01930890
Biogen Multiple Sclerosis Pregnancy Exposure Registry
NCT01911767
A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers
NCT01943513
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 135 |
| Phase 2 | 63 |
| Phase 3 | 71 |
| Phase 4 | 13 |
What is open in the Biogen pipeline
21 recruiting of 334 indexed (6% open); 237 completed (71%).
Phase mix: 84 late (III/IV) vs 198 early (I/II) (early-phase heavy).
Top condition: Multiple Sclerosis (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biogen: open-pipeline peers nationwide
Peers matched on 334 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Biogen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 334 trials (± recruiting share)
- National Institute on Drug Abuse (NIDA) · 335 trials · 4% recruiting
- Genentech · 332 trials · 7% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Altimmune · 6% recruiting · 16 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- Dynavax Technologies Corporation · 6% recruiting · 16 trials
Related
What to do with this Biogen page
334 registered trials is a research-attention snapshot, not an endorsement of Biogen or any single study.
- 21 of Biogen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition Biogen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biogen pipeline card: 334 registered trials from official public datasets.Report a data error.